Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

AQB vs PACB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PACB Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–3 Matrix Metrics)

PACB Overall Winner 6-Pillar Tally: AQB 2 – 3 PACB (1 Tie) Matrix Metrics: AQB 3 – 5 PACB

As of Nov 17, 2026, Pacific Biosciences of California, Inc. (PACB) is the stronger overall head-to-head candidate over AquaBounty Technologies, Inc. (AQB) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). AQB carries a Unified Composite Score of 44.6/100 (HOLD) at $0.82 (N/M Forward P/E, 0.0% operating margin), whereas PACB carries 50.1/100 (HOLD) at $1.82 (N/M Forward P/E, -333.0% operating margin).

  • Technical & Structure Timing Caution: AQB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5); meanwhile PACB is in a Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AQB vs PACB
AQB NASDAQ
AquaBounty Technologies, Inc.
Fishing, Hunting And Trapping
$0.82
+2.01% 1D
Market Cap $9.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.93β · 117% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 33.0 Fund 49.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.5%), weak momentum, RSI 37
RSI-14: 37.5 · SMA20: $1.04 · SMA50: $1.03
PACB NASDAQ Head-to-Head Winner
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.82
-1.09% 1D
Market Cap $574.5M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.24β · 109% Vol
Unified Composite Score
50.1 / 100 HOLD
Tech 27.0 Fund 46.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.9 · SMA20: $2.28 · SMA50: $2.02

6-Pillar Scorecard Institutional Category Breakdown (AQB 2 – 3 PACB)

Columns: Metric · AQB · PACB
1. Valuation Multiples PACB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 7.6x
2. Growth & Scale PACB
Revenue Growth (YoY) -93.5% +5.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $161M
Market Cap $9.7M $574.5M
3. Profitability & Quality AQB
Gross Margin N/A 27.7%
Operating Margin 0.0% -333.0%
Net Profit Margin 0.0% -81.3%
Return on Equity (ROE) -68.9% -929.3%
4. Balance Sheet & Cash Flow AQB
Cash Generation (TTM) -$7.2M -$150M
Cash Flow Margin N/A -93.2%
Net Cash / Leverage $0.19 Book/Sh · -68.9% ROE $649M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PACB
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 191.0% (97th %ile)
Put/Call OI Skew N/A 0.04x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Farm Products Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AQB (3) vs PACB (5)
Institutional Metric AQB PACB Criterion Row Edge
Market Capitalization
Scale
$9.7M $574.5M Larger Scale PACB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-93.5% +5.5% Higher Growth PACB
Operating Margin (TTM)
Profitability
0.0% -333.0% Higher Margin AQB
Net Profit Margin
Profitability
0.0% -81.3% Higher Margin AQB
Return on Equity (ROE)
Capital Efficiency
-68.9% -929.3% Higher ROE AQB
52-Week Range Position
Momentum
11% ($1–$2) 32% ($1–$3) Stronger Trend PACB
Beta / 30D Volatility
Risk Regime
0.93β · 117% Vol 2.24β · 109% Vol Lower Realized Risk PACB
Unified Institutional Score
Composite Signal
44.6 / 100 (HOLD) 50.1 / 100 (HOLD) Higher Composite PACB
Trailing 12M Revenue (USD)
Operating Scale
N/A $161M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 27.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.2M ($0.19 Book/Sh · -68.9% ROE) -$150M ($649M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACB +20.28 pp
AQB: -21.37% · PACB: -1.09%
3M Horizon PACB +81.82 pp
AQB: -38.51% · PACB: +43.31%
6M Horizon PACB +79.63 pp
AQB: -21.37% · PACB: +58.26%
1Y Horizon PACB +36.61 pp
AQB: -23.57% · PACB: +13.04%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AQB Revenue PACB Revenue AQB Op. Margin PACB Op. Margin Margin Leader
FY2018 $0M $80M -12264.6% -128.4% PACB
FY2019 $0M $90M -7057.3% -110.6% PACB
FY2020 $0M $80M -12727.1% -132.3% PACB
FY2021 $0M $130M -1883.0% -161.2% PACB
FY2022 $0M $130M -711.6% -239.4% PACB
FY2023 $0M $200M -552.9% -166.8% PACB
FY2024 N/A $150M N/A -308.0% PACB
FY2025 N/A $160M N/A -346.2% PACB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AQB BREAKDOWN
69d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AQB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
13d in phase · OBV DISTRIBUTION
Current IV 191.0%
IV Percentile 97th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AQB Moat Profile Cyclical / Execution-Driven Positioning
Farm Products Operator
Competes within the Farm Products value chain with $9.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $574.5M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AQB vs PACB Key Questions & Quantitative Answers

As of Nov 17, 2026, Pacific Biosciences of California, Inc. (PACB) is the stronger overall head-to-head candidate over AquaBounty Technologies, Inc. (AQB) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). AQB carries a Unified Composite Score of 44.6/100 (HOLD) at $0.82 (N/M Forward P/E, 0.0% operating margin), whereas PACB carries 50.1/100 (HOLD) at $1.82 (N/M Forward P/E, -333.0% operating margin). Technical & Structure Timing Caution: AQB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5); meanwhile PACB is in a Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PACB leads the Growth & Scale pillar: AQB posts -93.5% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PACB at +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AQB cumulative revenue shifted N/A while PACB shifted +100.0%. In operating R&D and SG&A reinvestment, AQB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PACB.

PACB screens cheaper on headline valuation multiples. AQB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.6x EV/Revenue (-93.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AQB (-68.9% ROE) versus PACB (-929.3% ROE) capital efficiency.

In options market volatility and institutional positioning, AQB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.93β · 117% Vol realized risk). By comparison, PACB carries 191.0% implied volatility (97th %ile, Extreme (>80th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 109% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.